Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Dermata Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Dermata Therapeutics, Inc.

DRMA DRMAW

Dermata Therapeutics, Inc.

About Dermata Therapeutics, Inc.

Dermata Therapeutics develops innovative topical dermatology products targeting skin diseases like acne, psoriasis, and hyperhidrosis, as well as aesthetic conditions. Utilizing proprietary Spongilla technology derived from natural freshwater sponges, their treatments aim for rapid, effective, and patient-friendly applications. Focused on unmet medical needs, the company collaborates with partners to develop and commercialize minimally invasive, natural-based therapies for medical and aesthetic markets worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Dermata Therapeutics, Inc.

1
1
Dermata Therapeutics, Inc. Dermata Therapeutics Reports $1.8 Million Net Loss in Q1 2026, Shifts Focus to DTC Skincare

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Dermata Therapeutics, Inc. Dermata Therapeutics Reports Strategic Shift to DTC Model and Financial Performance Update

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Dermata Therapeutics, Inc. Dermata Therapeutics Reports Q3 2025 Financial Results and Strategic Shift to OTC Products

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Dermata Therapeutics, Inc. Dermata Therapeutics Reports Decreased Net Loss and Increased Assets in Latest 10-Q Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Dermata Therapeutics, Inc. Dermata Therapeutics Reports Q1 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Dermata Therapeutics, Inc. Dermata Therapeutics Reports $12.3 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Dermata Therapeutics, Inc. Dermata Therapeutics Reports Net Loss of $3.2M in Q3 2024, Increases Research and Development Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments